With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link

The USD 6.9 billion financial opportunity (by 2030) within the bispecific antibody therapeutics market has been analyzed across the following segments:
 Therapeutic Area
 Autoimmune Disorders
 Eye Disorders
 Genetic Disorders
 Hematological Malignancies
 Infectious Diseases
 Inflammatory Disorders
 Skin Disorders

 Mechanism of Action
 Cytokines Retargeting / Neutralization
 Dual Ligands Blocking
 T-cell Retargeting / Activation
 Others

 Target Antigens
 CD3 x CD19
 CD30 x CD16A
 Factor IXa x Factor X
 IL-1α x IL-1β
 IL-13 x IL-4
 IL-17A x Albumin
 IL-17A x IL-17F
 Psl x PcrV
 VEGF-A x ANG2
 Others

 Antibody Formats
 Asymmetric
 Fragments
 Symmetric
 Others

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific

The Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:
 Amgen
 Ablynx
 AbbVie
 Affibody
 Affimed
 Alphamab
 AstraZeneca
 Avillion
 Chugai Pharmaceuticals
 Eddingpharm
 GSK
 Merck
 Merus
 Roche
 Regeneron Pharmaceuticals
 Taisho Pharmaceuticals
 Zymeworks

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Bispecific Antibody Therapeutics: Technology Platforms

6. Drug Profiles

7. Key Insights

8. Benchmark Analysis: Big Pharma Players

9. Partnerships and Collaborations

10. Contract Services for Bispecific Antibody Therapeutics

11. Clinical Trial Analysis

12. Case Study: Regulatory Guidelines for Bispecific Antibodies

13. Case Study: Promotional / Marketing Strategies

14. SWOT Analysis

15. Market Forecast and Opportunity Analysis

16. Concluding Remarks

17. Executive Insights

18. Appendix 1: Tabulated Data

19. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]